Pfizer stock has returned roughly 28.4% less over the past five years, yet the current valuation screens as somewhat expensive on market multiples and only mixed on the broader checks. That combination leaves investors weighing whether the recent recovery in the share price is already pricing in much of the good news from the company’s pipeline and product portfolio.
- Pfizer’s share price is down about 28.4% over five years, which suggests long term holders have experienced a material drag on returns despite more recent gains.
- The European review of Pfizer and Valneva’s Lyme disease vaccine candidate can support sentiment around future product contributions, while ongoing legal and regulatory issues such as the Chantix settlement highlight risks that may weigh on how investors assess the stock’s valuation.
- With a value score of 3 out of 6, Pfizer presents a mixed picture rather than a clear bargain or clear overvaluation when the broader set of valuation checks is considered.
For investors, the debate is whether Pfizer’s current price already reflects the expected contribution from its newer treatments and vaccines, given the mixed valuation read and weak five year return profile.
Find out why Pfizer's 14.0% return over the last year is lagging behind its peers.
Has Pfizer Run Too Far on Earnings?
The P/E ratio is a useful anchor for Pfizer because investors often focus on earnings power for established pharmaceutical companies. Pfizer currently trades on a P/E of 35.2x, which is more than double the wider pharmaceuticals industry average of 16.9x.
A tailored fair P/E ratio for Pfizer, based on its profile and risks, is 24.6x. That is well below the current 35.2x level and also below the peer group average of 52.5x. Even with recent news such as the European review of the Lyme disease vaccine candidate and stronger non Covid drug sales, the market is already assigning a premium to Pfizer’s earnings that is higher than this fair multiple.
On the P/E multiple, Pfizer stock currently screens as overvalued compared with both its modelled fair ratio and the broader pharmaceuticals industry.
See what the numbers say about this price — find out in our valuation breakdown.
The Pfizer Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this valuation puzzle for Pfizer leaves off by explaining what kind of future for growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price, and they sit on the Community page. Each Narrative ties a fair value to a specific story about Pfizer's potential catalysts and key risks so you can track over time which version of events is coming through in the numbers.
Community views on Pfizer sit far apart, with one camp focused on pipeline and margin recovery and the other on pricing pressure and patent risk.
Bull case: 8% undervalued
"Strategic business development and licensing (such as the 3SBio bispecific antibody deal and ongoing portfolio additions in high-value areas like oncology, immunology, and obesity) support revenue diversification and lifecycle management…"
Read the full Bull Case to see why Pfizer could be undervalued
Bear case: 7% overvalued
"The company's revenue trajectory is threatened by the accelerating loss of market exclusivity on major drugs such as Eliquis and Ibrance, both of which are expected to lose patent protection by 2027…"
Read the full Bear Case to see why Pfizer could be overvalued
Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!
The Bottom Line
Pfizer screens as overvalued on its current P/E multiple, so the market is already paying up for the earnings it sees ahead. The mixed value checks underline that there is no clear margin of safety built into today’s price. From here, the key question is whether Pfizer can translate its pipeline, product mix and cost efforts into the kind of earnings and margin profile that keeps justifying a premium multiple, rather than leaving the stock exposed if expectations cool.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com